Skip to main content

Table 2 Association of the TyG index with the absolute change, change rate and slope of baPWV

From: Association of TyG index and TG/HDL-C ratio with arterial stiffness progression in a non-normotensive population

 

model 1

model 2

model 3

β

95% CI

P value

β

95% CI

P value

β

95% CI

P value

Change of baPWV (cm/s)

 TyG (continuous)

32.034

4.642–59.425

0.022

57.119

22.835–91.402

0.001

149.582

90.823–208.342

< 0.001

 Quartile 2 (ref: quartile 1)

59.745

10.509–108.982

0.017

61.086

12.582–109.59

0.014

76.297

28.63–123.964

0.002

 Quartile 3

85.613

36.416–134.81

0.001

93.631

43.889–143.373

< 0.001

102.562

52.08–153.044

< 0.001

 Quartile 4

74.957

25.494–124.42

0.003

98.555

37.584–159.526

0.002

129.525

58.723–200.326

< 0.001

 P for trend

  

0.002

  

< 0.001

  

< 0.001

Change rate of baPWV (cm/s/year)

 TyG (continuous)

11.892

3.415–20.368

0.006

17.974

7.307–28.642

0.001

40.372

21.853–58.891

< 0.001

 Quartile 2 (ref: quartile 1)

11.870

-3.385–27.125

0.127

12.122

-2.986–27.229

0.116

16.529

1.507–31.551

0.031

 Quartile 3

20.615

5.373–35.858

0.008

22.642

7.149–38.135

0.004

24.390

8.481–40.299

0.003

 Quartile 4

24.616

9.291–39.941

0.002

30.750

11.76–49.741

0.002

37.607

15.294–59.919

0.001

 P for trend

  

0.001

  

0.001

  

< 0.001

Slope of baPWV

 TyG (continuous)

9.570

1.538–17.601

0.020

14.238

4.121–24.355

0.006

34.874

17.238–52.51

< 0.001

 Quartile 2 (ref: quartile 1)

10.986

-3.469–25.441

0.136

10.888

-3.439–25.215

0.137

14.872

0.57–29.175

0.042

 Quartile 3

18.739

4.296–33.182

0.011

20.092

5.399–34.785

0.007

22.163

7.016–37.31

0.004

 Quartile 4

20.126

5.604–34.647

0.007

23.648

5.639–41.658

0.010

30.576

9.332–51.82

0.005

 P for trend

  

0.004

  

0.003

  

0.002

  1. Model 1: Adjusted age and sex; Model 2: Age, sex, BMI, smoking status, drinking status, physical activity, diabetes, dyslipidaemia, baPWV at baseline, and MAP at baseline and follow-up; Model 3: Model 2 plus FBG, triglyceride, PBG, LDL-C, eGFR, uric acid, homocysteine, and use of antidiabetic, lipid-lowering, or antihypertensive medications at baseline and follow-up
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840